RESUMEN
BACKGROUND: Ultraviolet (UV) A1 phototherapy is considered a beneficial treatment for various inflammatory, sclerotic, malignant, and other skin conditions. However, the available data regarding its efficacy for different indications, the potential side effects, and the recommended treatment protocols are sparse. OBJECTIVES: To assess the efficacy of UVA1 phototherapy and identify correlation between different indications and treatment protocols to response rates. METHODS: We performed a retrospective study of a cohort of 335 patients treated with UVA1 phototherapy at the Department of Dermatology at Hadassah Medical Center, Jerusalem, Israel, between 2008 and 2018. RESULTS: The study population included 163 patients with inflammatory diseases (mainly atopic dermatitis and other types of eczema), 67 patients with sclerotic diseases (morphea and graft versus host disease), nine patients with neoplastic diseases (cutaneous T cell lymphoma), and 188 patients with other cutaneous disorders. Response rates ranged between 85% and 89% across indications, without differences in response rates among the indication groups (p = .941). In a multivariant logistic regression model, increased number of treatments and higher maximal dosages were associated with response to treatment (p < .001). Using ROC analysis, a cut-off of 8 UVA1 phototherapy treatments was chosen as predictive for beneficial response (86.4% sensitivity, 78% specificity). A cut-off of 40 J/cm2 was chosen as an optimal maximal dosage for differentiating between responders and non-responders (51.1% sensitivity, 83.1% specificity). CONCLUSIONS: UVA1 phototherapy is an effective treatment for a variety of skin conditions. In most patients, at least eight treatments of a medium-high dosage are required for clinical response.
Asunto(s)
Esclerodermia Localizada , Neoplasias Cutáneas , Terapia Ultravioleta , Humanos , Terapia Ultravioleta/efectos adversos , Estudios Retrospectivos , Centros de Atención Terciaria , Esclerodermia Localizada/etiología , Esclerodermia Localizada/patología , Resultado del Tratamiento , Neoplasias Cutáneas/etiología , FototerapiaRESUMEN
Morphea, or localized scleroderma, is a rare disease of the connective tissue that manifests itself with localized sclerosis of the skin and, in some cases, with extracutaneous manifestations. Its etiology is not fully understood, but it is believed that there is genetic predisposition, in addition to environmental triggering factors. Classification of the disease is not simple due to its multiple presentations; however, it is useful in order to define the treatment, which should be individualized and started early to avoid cosmetic and functional complications. In this review, we summarize the most important practical aspects of the classification, diagnostic methods and evaluation of morphea activity, as well as available therapeutic options, with an emphasis on existing clinical evidence regarding their efficacy and safety.
Asunto(s)
Humanos , Masculino , Femenino , Esclerodermia Localizada/clasificación , Esclerodermia Localizada/diagnóstico , Esclerodermia Localizada/etiología , Esclerodermia Localizada/terapia , Fototerapia/métodos , Pronóstico , Índice de Severidad de la Enfermedad , Factores Sexuales , Terapia por Ejercicio , InmunosupresoresRESUMEN
Morphea, or localized scleroderma, is a rare disease of the connective tissue that manifests itself with localized sclerosis of the skin and, in some cases, with extracutaneous manifestations. Its etiology is not fully understood, but it is believed that there is genetic predisposition, in addition to environmental triggering factors. Classification of the disease is not simple due to its multiple presentations; however, it is useful in order to define the treatment, which should be individualized and started early to avoid cosmetic and functional complications. In this review, we summarize the most important practical aspects of the classification, diagnostic methods and evaluation of morphea activity, as well as available therapeutic options, with an emphasis on existing clinical evidence regarding their efficacy and safety.
Asunto(s)
Esclerodermia Localizada , Terapia por Ejercicio , Femenino , Humanos , Inmunosupresores , Masculino , Fototerapia/métodos , Pronóstico , Esclerodermia Localizada/clasificación , Esclerodermia Localizada/diagnóstico , Esclerodermia Localizada/etiología , Esclerodermia Localizada/terapia , Índice de Severidad de la Enfermedad , Factores SexualesRESUMEN
La morfea es una enfermedad de la piel que se manifiesta en forma de inflamación y fibrosis. En niños y jóvenes, también se conoce como esclerodermia juvenil localizada. En edad infantil, afecta con mayor frecuencia al sexo femenino y la edad de comienzo se ha establecido en torno a los 5-7 años. Una clasificación reciente divide la morfea en: circunscrita (en placas), lineal, generalizada, panesclerótica y mixta. Alrededor de un 40% de los pacientes presentan manifestaciones extracutáneas. Los tratamientos empleados en morfea infantil son: fototerapia, calcitriol oral, calcipotriol tópico, tacrolimus 0,1% tópico, metotrexato, glucocorticoides tópicos y sistémicos, mofetil micofenolato, bosentán e imiquimod 5% tópico. Diversas medidas de resultado pueden ayudar a monitorizar el tratamiento. Los estudios pronósticos son escasos, pero apuntan hacia una enfermedad con tendencia a un curso crónico o intermitente-recurrente y una frecuencia considerable de secuelas
Morphea is an inflammatory, fibrosing skin disorder. When it occurs in childhood, it is also known as localized juvenile scleroderma. It is more common in girls and typically appears around the age of 5 to 7 years. According to a recent classification system, morphea is divided into 5 types: circumscribed (plaque), linear, generalized, pansclerotic, and mixed. Approximately 40% of patients present extracutaneous manifestations. Childhood morphea is treated with phototherapy, oral or topical calcitriol, topical tacrolimus 0.1%, methotrexate, topical or systemic corticosteroids, mycophenolate mofetil, bosentán, and topical imiquimod 5%. A variety of measuring tools are used to monitor response to treatment. Few prognostic studies have been conducted, but findings to date suggest that the disease tends to run a chronic or intermittent-recurrent course and frequently causes sequelae
Asunto(s)
Humanos , Masculino , Femenino , Lactante , Preescolar , Niño , Adolescente , Esclerodermia Localizada/epidemiología , Esclerodermia Localizada/tratamiento farmacológico , Esclerodermia Localizada/diagnóstico , Fototerapia/métodos , Pronóstico , Esclerodermia Localizada/etiología , Esclerodermia Localizada/patología , Vitamina D/uso terapéutico , Factores Inmunológicos/uso terapéuticoAsunto(s)
Vacunas contra la Influenza/efectos adversos , Liquen Escleroso y Atrófico/etiología , Esclerodermia Localizada/etiología , Anciano , Neoplasias de la Mama , Femenino , Humanos , Liquen Escleroso y Atrófico/tratamiento farmacológico , Metotrexato/uso terapéutico , Terapia PUVA , Prednisona/uso terapéutico , Esclerodermia Localizada/tratamiento farmacológicoAsunto(s)
Traumatismos por Radiación/tratamiento farmacológico , Esclerodermia Localizada/tratamiento farmacológico , Adulto , Anciano , Femenino , Humanos , Persona de Mediana Edad , Terapia PUVA , Traumatismos por Radiación/etiología , Traumatismos por Radiación/terapia , Radioterapia/efectos adversos , Estudios Retrospectivos , Esclerodermia Localizada/etiología , Esclerodermia Localizada/terapiaRESUMEN
Graft-versus-host disease (GVHD) is one of the major complications after hematopoietic stem cell transplantation and is responsible for post-therapeutic morbidity, mortality, and poor quality of life of recipients. Sclerodermatous graft-versus-host disease (sGVHD) is a rare variant of chronic GVHD characterized by deposition of collagen in the skin and other soft tissues and resulting in loss of range of motion and functional capabilities. Treatment of sGVHD is challenging and largely limited by systemic side effects. Ultraviolet A1 phototherapy has been reported to be effective in connective tissue disorders, including sGVHD. We report a case of sGVHD in a 15-year-old girl that was resistant to traditional therapy but showed improvement in cutaneous symptoms with ultraviolet A1 phototherapy three times a week for 6 weeks (10 J/cm(2) single dose, 180 J/cm(2) cumulative dose).
Asunto(s)
Enfermedad Injerto contra Huésped/tratamiento farmacológico , Terapia PUVA/métodos , Esclerodermia Localizada/tratamiento farmacológico , Adolescente , Femenino , Enfermedad Injerto contra Huésped/complicaciones , Humanos , Esclerodermia Localizada/etiologíaRESUMEN
BACKGROUND: Skin trauma may play a role in the development of morphea lesions. The association between trauma and the distribution of cutaneous lesions has never been examined to our knowledge. OBJECTIVE: We sought to determine whether patients enrolled in the Morphea in Adults and Children (MAC) cohort exhibit skin lesions distributed in areas of prior (isotopic) or ongoing (isomorphic) trauma. METHODS: This was a cross-sectional analysis of the MAC cohort. RESULTS: Of 329 patients in the MAC cohort, 52 (16%) had trauma-associated lesions at the onset of disease. Patients with lesions in an isotopic distribution had greater clinical severity as measured by a clinical outcome measure (mean modified Rodnan Skin Score of 13.8 vs 5.3, P = .004, 95% confidence interval 3.08-13.92) and impact on life quality (mean Dermatology Life Quality Index score 8.4 vs 4.1, P = .009, 95% confidence interval 1.18-7.50) than those with an isomorphic distribution. Most frequent associated traumas were chronic friction (isomorphic) and surgery/isotopic. LIMITATIONS: Recall bias for patient-reported events is a limitation. CONCLUSION: Of patients in the MAC cohort, 16% developed initial morphea lesions at sites of skin trauma. If these findings can be confirmed in additional series, they suggest that elective procedures and excessive skin trauma or friction might be avoided in these patients.
Asunto(s)
Esclerodermia Localizada/etiología , Piel/lesiones , Adulto , Estudios de Cohortes , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fototerapia , Calidad de Vida , Esclerodermia Localizada/terapia , Índice de Severidad de la EnfermedadRESUMEN
Morphoea is a localized inflammatory disorder of the dermis and subcutaneous fat and radiotherapy is a rarely reported cause (estimated incidence of 2 per 1000). Morphoea is commonly mistaken for an inflammatory recurrence of breast cancer, resulting in unnecessary investigations and treatment. We report the case of a 40-year-old woman who developed radiation-induced morphoea of the breast 7 months following adjuvant radiotherapy. She was treated with topical and systemic steroids as well as psoralen plus ultraviolet (UV)A before proceeding to UVA1 phototherapy. We also review the literature and discuss other management options.
Asunto(s)
Traumatismos por Radiación/radioterapia , Radioterapia Adyuvante/efectos adversos , Esclerodermia Localizada/radioterapia , Terapia Ultravioleta/métodos , Adulto , Neoplasias de la Mama/radioterapia , Femenino , Humanos , Esclerodermia Localizada/etiología , Resultado del TratamientoRESUMEN
Morphoea is a localized scleroderma. Since the 1990s, it is described as a complication after irradiation for breast cancer. This complication is unrecognized and underdiagnosed. Irradiation seems to be a factor inducing an autoimmune process. Clinicians should be aware in case of an erythema in a treated area, appearing on average one year after the end of the irradiation. Histology alone can prove the diagnosis and rule out differential diagnoses: principally mastitis (carcinomatous, infectious), chronic radiodermatitis or radiation recall. Treatment of this rare complication is not consensual; it is most often topical steroids. The evolution is marked by a gradual decrease from the initial inflammation. Sclerosis persists, more or less substantially.
Asunto(s)
Enfermedades Autoinmunes/etiología , Enfermedades de la Mama/etiología , Neoplasias de la Mama/radioterapia , Esclerodermia Localizada/etiología , Antibacterianos/uso terapéutico , Antimetabolitos/uso terapéutico , Autoanticuerpos/sangre , Enfermedades Autoinmunes/diagnóstico , Enfermedades Autoinmunes/patología , Enfermedades Autoinmunes/terapia , Enfermedades de la Mama/diagnóstico , Enfermedades de la Mama/patología , Enfermedades de la Mama/terapia , Desbridamiento , Progresión de la Enfermedad , Eritema/etiología , Femenino , Humanos , Inmunosupresores/uso terapéutico , Fototerapia , Radiodermatitis/diagnóstico , Radiodermatitis/etiología , Radiodermatitis/patología , Radiodermatitis/terapia , Esclerodermia Localizada/diagnóstico , Esclerodermia Localizada/patología , Esclerodermia Localizada/terapiaRESUMEN
Scleroderma refers to a heterogeneous group of autoimmune fibrosing disorders. The nomenclature of scleroderma has changed dramatically in recent years, with morphea (localized scleroderma), limited cutaneous systemic sclerosis, diffuse cutaneous systemic sclerosis, and systemic sclerosis sine scleroderma encompassing the currently accepted disease subtypes. Major advances have been made in the molecular studies of morphea and systemic sclerosis; however, their etiologies and pathogenesis remain incompletely understood. Although morphea and systemic sclerosis demonstrate activation of similar inflammatory and fibrotic pathways, important differences in signaling pathways and gene signatures indicate they are likely biologically distinct processes. Morphea can cause significant morbidity but does not affect mortality, whereas systemic sclerosis has the highest disease-specific mortality of all autoimmune connective tissue diseases. Treatment recommendations for morphea and systemic sclerosis are based on limited data and largely expert opinions. Current collaborative efforts in morphea and systemic sclerosis research will hopefully lead to better understanding of the etiology and pathogenesis of these rare and varied diseases and improved treatment options.
Asunto(s)
Esclerodermia Localizada , Esclerodermia Sistémica , Terminología como Asunto , Fármacos Dermatológicos/uso terapéutico , Humanos , Inmunosupresores/uso terapéutico , Fototerapia/métodos , Pronóstico , Esclerodermia Localizada/tratamiento farmacológico , Esclerodermia Localizada/etiología , Esclerodermia Sistémica/tratamiento farmacológico , Esclerodermia Sistémica/etiología , Índice de Severidad de la EnfermedadRESUMEN
Chronic cutaneous graft-versus-host disease (GVHD) classically presents with lichenoid papules or sclerotic plaques. This case highlights an unusual clinical manifestation of chronic GVHD and demonstrates that the skin morphology of chronic GVHD and cutaneous lymphoma may be similar. We report for the first time a case of annular scleroderma-like graft-versus-host disease in a patient following allogeneic stem cell transplant for CD30+ anaplastic large cell lymphoma. Treatment of these skin lesions with ultraviolet A1 (UVA1) phototherapy resulted in significant improvement.
Asunto(s)
Enfermedad Injerto contra Huésped/complicaciones , Trasplante de Células Madre Hematopoyéticas , Enfermedad de Hodgkin/terapia , Linfoma de Células B Grandes Difuso/terapia , Linfoma Cutáneo de Células T/terapia , Esclerodermia Localizada/etiología , Enfermedades de la Piel/terapia , Neoplasias Cutáneas/terapia , Enfermedad Injerto contra Huésped/patología , Humanos , Masculino , Persona de Mediana Edad , Terapia PUVA , Fototerapia , Esclerodermia Localizada/patologíaRESUMEN
Morphea and other scleroderma-like skin conditions are occasionally linked with exposure to chemical compounds such as silicone. We treated a 56-year-old woman with generalized severe skin induration accompanied with systemic symptoms and peripheral eosinophilia, which appeared 2.5 years after breast silicone implantation and abdominal liposuction. Blood test results and histopathological examination of her skin suggested the diagnosis of morphea overlapping with eosinophilic fasciitis. Her skin disease was presumed to be an autoimmune reaction to silicone implantation. While the removal of the implants did not improve her illness, treatment with 1 mg/kg prednisone and PUVA bath was initiated, with some improvement. This patient illustrates an example of ASIA (Autoimmune Syndrome Induced by Adjuvants), as her disease appeared following exposure to an adjuvant stimulus, with 'typical', although not well-defined, autoimmune manifestations.
Asunto(s)
Adyuvantes Inmunológicos/efectos adversos , Enfermedades Autoinmunes/inducido químicamente , Implantes de Mama/efectos adversos , Esclerodermia Localizada/etiología , Esclerodermia Localizada/inmunología , Siliconas/efectos adversos , Enfermedades Autoinmunes/inmunología , Eosinofilia/etiología , Eosinofilia/inmunología , Eosinofilia/patología , Fascitis/etiología , Fascitis/inmunología , Fascitis/patología , Femenino , Humanos , Persona de Mediana Edad , Medio Oriente , Esclerodermia Localizada/patologíaRESUMEN
Localized scleroderma is a chronic inflammatory disease primarily of the dermis and subcutaneous fat that ultimately leads to a scar-like sclerosis of connective tissue. The disorder manifests as various plaques of different shape and size with signs of skin inflammation, sclerosis, and atrophy. This is a relatively rare inflammatory disease characterized by a chronic course, unknown etiology, and insufficiently clear pathogenesis. Many factors may influence its appearance: trauma, genetic factors, disorders of the immune system or hormone metabolism, viral infections, toxic substances or pharmaceutical agents, neurogenic factors, and Borrelia burgdorferi infection. Various therapeutic modalities are being used for the treatment of localized scleroderma. There is no precise treatment scheme for this disease. A majority of patients can be successfully treated with topical pharmaceutical agents and phototherapy, but some of them with progressive, disseminated, and causing disability localized scleroderma are in need of systemic treatment. The aim of this article is not only to dispute about the clinical and morphological characteristics of localized scleroderma, but also to present the newest generalized data about the possible origin, pathogenesis, and treatment modalities of this disease.
Asunto(s)
Esclerodermia Localizada/etiología , Esclerodermia Localizada/terapia , Humanos , Esclerodermia Localizada/diagnóstico , Esclerodermia Localizada/patologíaRESUMEN
Localized scleroderma is a rare autoimmune disease with primary affection of the skin, and occasional involvement of the fat tissue, muscle, fascia, and bone. Depending on the clinical subtype, the spectrum of skin lesions ranges from singular plaque lesions to severe generalized or linear subtypes which may lead to movement restrictions and permanent disability. This German S1-guideline proposes a classification of localized scleroderma that, considering the extent and depth of fibrosis, distinguishes limited, generalized, linear, and deep forms of localized scleroderma, together with its associated subtypes. The guideline includes a description of the pathogenesis, of differential diagnoses, and particular aspects of juvenile localized scleroderma, as well as recommendations for histopathologic, serologic, and biometric diagnostic procedures. Based on studies of topical and systemic treatments as well as phototherapy for localized scleroderma published in international literature, a treatment algorithm was developed which takes account of the different subtypes and the extent of disease.
Asunto(s)
Medicina Basada en la Evidencia , Esclerodermia Localizada/diagnóstico , Adolescente , Adulto , Niño , Terapia Combinada , Humanos , Esclerodermia Localizada/clasificación , Esclerodermia Localizada/etiología , Esclerodermia Localizada/terapia , Resultado del TratamientoRESUMEN
HISTORY AND CLINICAL FINDINGS: A 46-year-old man presented with suberythrodermia and an acral-accentuated sclerosis, which had been progressing over the past 6 months, with extensive, painful ulcers within the sclerotic areas of the calf. Due to acute myelotic leukemia (AML), an allogenic peripheral blood stem-cell transplantation with subsequent immunosupression with mycophenolatmofetil (MMF) and ciclosporin A had been performed 8 years previously. The patient had discontinued treatment on his own after about 2 years, having suffered a cerebroischemic insult in the meantime. INVESTIGATIONS: Histological examinations revealed sclerodermatous changes. Titres of antinuclear antibodies were unremarkable. Laser-Doppler-flowmetry also indicated an active inflammatory and sclerosing process. FACS analysis of the peripheral blood did not reveal signs of AML recurrence. DIAGNOSIS, THERAPY AND COURSE: The histological pattern in conjunction with the anamnesis indicated a cutaneous chronic graft-versus-host disease (GvHD). No further organ involvement was observed. The MMF therapy which the patient had discontinued was restarted. In addition, PUVA therapy was initiated. These measures and intensive physiotherapeutic exercises in parallel prevented further progression of the sclerosis and secondary mobility limitations. The ulcers healed completely with pentoxifylline and anti-infective treatment. CONCLUSION: After stem-cell transplantation, early diagnosis of GvHD is especially important due to possible irreversible sclerodermatous changes and other organ manifestations. Also for this reason, strict clinical follow-up is especially important with respect to compliance and efficacy of the immunosuppression.
Asunto(s)
Enfermedad Injerto contra Huésped/etiología , Leucemia Mieloide Aguda/terapia , Trasplante de Células Madre de Sangre Periférica/efectos adversos , Esclerodermia Localizada/etiología , Antiinfecciosos/uso terapéutico , Ciclosporina/uso terapéutico , Enfermedad Injerto contra Huésped/diagnóstico , Enfermedad Injerto contra Huésped/terapia , Humanos , Inmunosupresores/uso terapéutico , Flujometría por Láser-Doppler , Úlcera de la Pierna/diagnóstico , Úlcera de la Pierna/etiología , Úlcera de la Pierna/terapia , Masculino , Persona de Mediana Edad , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapéutico , Terapia PUVA , Cooperación del Paciente , Pentoxifilina/uso terapéutico , Modalidades de Fisioterapia , Esclerodermia Localizada/diagnóstico , Esclerodermia Localizada/terapia , Trasplante Homólogo , Vasodilatadores/uso terapéuticoRESUMEN
PURPOSE OF REVIEW: Localized scleroderma, also known as morphea, is the most frequent form of scleroderma in childhood. Early diagnosis, appropriate assessment and effective treatment may improve the long-term outcome. RECENT FINDINGS: Recent studies, regarding the microchimerism theory or the mechanism of action of phototherapy, have yielded important information on the disease etiopathogenesis. Others have added interesting contributions on new outcome measures for the disease assessment and for the development of future therapeutic trials. Previous results, using methotrexate and phototherapy, have been confirmed. A successful use of bosentan, an endothelin receptor antagonist with vasodilatative and antifibrotic properties for refractory cutaneous ulcerations in pansclerotic morphea, opens new horizons of treatment. SUMMARY: Studies over the past year highlight the role of some outcome measures in the disease assessment and monitoring, with important implications both for the clinical practice and future clinical trials.
Asunto(s)
Fototerapia/tendencias , Esclerodermia Localizada/diagnóstico , Esclerodermia Localizada/terapia , Índice de Severidad de la Enfermedad , Ensayos Clínicos como Asunto , Humanos , Esclerodermia Localizada/etiología , Resultado del TratamientoRESUMEN
Skin scleroderma (LS) is characterised by stiffness of skin and/or deeper tissues. As opposed to systemic scleroderma, the involvement of internal organs and Raynaud phenomenon are predominately not observed in morphea. LS is quite rare disease, more frequent in women and young people. There are several useful classifications of skin scleroderma in literature, however the classification which concerns the shape and extension of LS lesion and depth of stiffness is concerned to be the most clear. LS is divided into: plaque morphoea, generalised morphoea, blistering morphoea, linear morphoea and deep morphoea. Different types of skin scleroderma lesions can be observed in one patient or can combine linear and deep fibrosis. Presented classification is clinically useful and it has prognostic and therapeutic implications.
Asunto(s)
Esclerodermia Localizada/diagnóstico , Esclerodermia Localizada/etiología , Adolescente , Niño , Preescolar , Diagnóstico Diferencial , Femenino , Humanos , Terapia PUVA , Esclerodermia Localizada/fisiopatología , Esclerodermia Sistémica/diagnóstico , Esclerodermia Sistémica/etiología , Esclerodermia Sistémica/fisiopatología , Piel/metabolismo , Piel/patología , Piel/fisiopatologíaRESUMEN
Sclerodermatous graft-versus-host disease (GVHD) is a rare complication of bone marrow transplantation. While GVHD is often associated with the beneficial graft vs. tumour effect, it also contributes towards significant morbidity and mortality. No reliably effective treatment has yet been established. We present 10 patients with haematological malignancies who underwent an allogeneic stem cell transplant and developed sclerodermatous GVHD. Donor lymphocyte infusion administered for relapse or reducing donor T-cell chimerism was a known trigger for sclerodermatous GVHD in four of the patients. Treatment with immunosuppressants, psoralen plus ultraviolet A (PUVA) and extracorporeal photopheresis has been largely unsuccessful in their management. Intensive immunosuppression including the use of anti-CD20 monoclonal antibody may have contributed to relapse of leukaemia in one patient 10 years after her transplant. Sclerodermatous GVHD may occur without a preceding lichenoid stage. Clinical heterogeneity is common, although sclerodermatous GVHD has a predilection for the limbs. Treatment options are largely unsatisfactory if conventional immunosuppression fails. PUVA may give some symptomatic benefit and extracorporeal photopheresis seems to be less efficacious than previously published work suggests.